A Study in Adult Subjects With Select Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-09

Study Completion Date

2018-12-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and tolerability of MEDI1873 in adult subjects with selected advanced solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

NCT02318394

Advanced Solid Tumors

COMPLETED PHASE1

Dendritic Cell Vaccination for Patients with Solid Tumors

NCT01291420

Glioblastoma Renal Cell Carcinoma Sarcomas +3 more

COMPLETED PHASE1/PHASE2

Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors

NCT04765462

Malignant Solid Tumours

UNKNOWN PHASE1/PHASE2

Immune Cell Therapy for Advanced Solid Tumors

NCT07260058

Lung Cancer (Locally Advanced or Metastatic) Liver Cancer (Locally Advanced or Metastatic) Colorectal Cancer (Locally Advanced or Metastatic) +2 more

NOT_YET_RECRUITING PHASE1/PHASE2

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

NCT01875653

Stage IV Melanoma Stage III Melanoma

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a first-time-in-human, Phase 1, multicenter, open-label, single-arm dose-escalation study of MEDI1873 to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and anti-tumor activity in adult subjects with advanced solid tumor malignancies

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Monotherapy arm

MEDI1873

Group Type EXPERIMENTAL

MEDI1873

Intervention Type BIOLOGICAL

Subjects will receive MEDI1873 by intravenous administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MEDI1873

Subjects will receive MEDI1873 by intravenous administration

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All subjects must consent to provide archived tumor specimen
* Subjects must have histologically or cytologically confirmed advanced solid tumor for recurrent or metastatic disease.
* At the time of Day 1 of the study, subjects with central nervous system (CNS) metastases must have been treated and must be asymptomatic
* Willingness to provide pretreatment and on-treatment biopsies.
* Adequate organ function
* Females of childbearing potential and nonsterilized males who are sexually active must use effective methods of contraception

Exclusion Criteria

* Known allergic reaction to any component of MEDI1873
* Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow-up period of an interventional study
* Receipt of any anticancer therapy within 4 weeks prior to the first dose of MEDI1873; in the case of mAbs, 6 weeks prior to the first dose of MEDI1873
* Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment.
* Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational product
* Unresolved toxicities from prior anticancer therapy
* Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No